about
Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugsHigh-Dose Verapamil in Episodic and Chronic Cluster Headaches and Cardiac Adverse Events: Is It as Safe as We Think?Agonists Bay-K8644 and CGP-28392 open calcium channels reconstituted from skeletal muscle transverse tubulesCardiovascular effects of substituted tetrahydroisoquinolines in rats.Identification of a novel calcium antagonist binding site in rat brain by SR 33557Inotropic effects of Ca2+ channel agonist and antagonists in neuraminidase-treated left atria of ratsCharacterization of [3H]-nitrendipine binding to uterine smooth muscle plasma membrane and its relevance to inhibition of calcium entry.Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart.Differential antagonism by Bay k 8644, a dihydropyridine calcium agonist, of the negative inotropic effects of nifedipine, verapamil, diltiazem and manganese ions in canine ventricular muscle.Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cellsAntischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists.Brain voltage-sensitive calcium channel subtypes differentiated by omega-conotoxin fraction GVIA.Calcium channel activation: a different type of drug action.The molecular pharmacology and structural features of calcium channelsCalcium antagonist receptors. Clinical and physiological relevance.Molecular properties of dihydropyridine-sensitive calcium channels.Calcium channel blockers and cardiac surgery.Clinical studies with calcium antagonists in asthma.Selectivity of calcium antagonist drugs on vascular smooth muscle.Dual calcium-channel blocker therapy in the treatment of hypertension.Calcium-channel blockers and asthma.Glucocorticoids increase Ca2+ uptake and [3H]dihydropyridine binding in A7r5 vascular smooth muscle cells.Comparative potencies of calcium channel antagonists and antischizophrenic drugs on central and peripheral calcium channel binding sites.Selective modulation by membrane potential of the interaction of some calcium entry blockers with calcium channels in rat mesenteric artery.Evidence for a selective localization of voltage-sensitive Ca2+ channels in nerve cell bodies of corpus striatum.Reversible dihydropyridine isothiocyanate binding to brain calcium channels.Functional interactions of calcium-antagonists in K+-depolarized smooth muscle.Interaction of pinaverium (a quaternary ammonium compound) with 1,4-dihydropyridine binding sites in rat ileum smooth muscle.BAY K 8644, a 1,4-dihydropyridine Ca2+ channel activator: dissociation of binding and functional effects in brain synaptosomes.Characterization of the effects of omega-conotoxin GVIA on the responses of voltage-sensitive calcium channels.Effects of temperature and allosteric modulators on [3H] nitrendipine binding: methods for detecting potential Ca2+ channel blockers.Maitotoxin-evoked gamma-aminobutyric acid release is due not only to the opening of calcium channels.Effect of ethanol on [3H]nitrendipine binding to calcium channels in brain membranes.
P2860
Q27727732-20B776AB-63D1-4586-AC0E-97BA83B3217DQ33167805-582746EA-5A3C-4386-A402-D77D346CDEECQ34256939-32D451B8-ACF8-4679-9208-9AB400BC48EBQ35870792-167E7960-287F-43C0-908D-7807505A60EEQ35870980-4CF06B75-52F5-456E-9403-1312675D6F33Q35886395-D8EC6127-BB1A-449B-A9F0-533735C0BE46Q35886596-656975C7-6F9B-47B4-A934-901B5D78BAFCQ36003980-5A7F78B3-F794-4C98-A6DB-2FD81594D4CEQ36004512-4A064680-6F98-4776-B7E5-963918C6398EQ36409432-EC28A0DD-4C51-436F-90A2-310FC9774707Q37346562-4BA00C71-1B8E-481C-AFB1-0077985DBBA9Q37408344-4796577C-C76F-486C-8B70-918BC7CC2477Q37566948-8B2F9AE8-74D5-46F9-A6FF-05435C05A3E3Q38153848-CC693514-1B49-41C9-ABEC-30B088F4EDD4Q38188963-BA1ACDAE-BE34-4A78-9840-3586D44CD9E8Q38188967-648806C1-9C42-4E91-878D-E1A9ED99AA5BQ39491495-9396D6DE-BB04-406F-9A3C-49CBD8F33657Q39831623-53FE504F-1739-4AEB-BA44-6285F0A2F873Q40813844-5DF26877-B010-4AC3-B51D-AC3FCE229146Q40934869-8EE19578-1FF5-4C2B-B714-57251EAF767FQ41120190-E361AB75-FAFD-4BC8-8706-CCE53E130516Q41678200-82AACD8A-E978-453D-8242-F72DD1F77D8EQ41787003-FAB83640-D0AE-4835-B29C-FD8614E6C008Q41867528-093FB800-8F38-449C-BE61-9A280C1FA9BEQ42113422-85424EE8-FB2C-4455-A1ED-509A2BFF1E3BQ42191201-57ACA5FE-9EB1-46B7-863A-189191A11E96Q42636352-B3083A22-5599-4F8F-B158-906415226A9FQ42710284-AF0ECB7E-0F7F-4842-AE6E-99CFC354EF85Q46447556-5D4889E7-4EC5-4BAF-91F2-C29F9D19A9ABQ46920380-EDE97818-B620-42AF-8DB1-D4ACD6CC5190Q46965808-A9059480-2EE6-4721-A27E-E0C4E90F842CQ48097986-7A375A7A-510E-4420-A477-E255A268EFDBQ48610547-EB674BB5-35C1-4CBC-B4F7-2E0AF1ECBC4C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1983
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A unitary mechanism of calcium antagonist drug action.
@en
A unitary mechanism of calcium antagonist drug action.
@nl
type
label
A unitary mechanism of calcium antagonist drug action.
@en
A unitary mechanism of calcium antagonist drug action.
@nl
prefLabel
A unitary mechanism of calcium antagonist drug action.
@en
A unitary mechanism of calcium antagonist drug action.
@nl
P2093
P2860
P356
P1476
A unitary mechanism of calcium antagonist drug action.
@en
P2093
B L Largent
K M Murphy
S H Snyder
P2860
P304
P356
10.1073/PNAS.80.3.860
P407
P577
1983-02-01T00:00:00Z